SCHEMBL27285282

SCHEMBL27285282

O=C(O)[C@@H]1C[C@@H](F)CN1C(=O)C1(C(F)(F)F)CCOCC1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.33
EP300 Q09472 1/20 0.32
LGMN Q99538 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25381544 0.90 ATM (0.37) ATMLGMN
SCHEMBL31276598 0.87 ATM (0.35) ATMEP300LGMN
SCHEMBL27393371 0.86 ATM (0.34) ATMEP300
SCHEMBL27285081 0.85 ATM (0.33) ATMEP300LGMN
SCHEMBL30819603 0.85 PEPD (0.41) EP300LGMN
SCHEMBL27285277 0.82 ATM (0.35) ATMEP300
SCHEMBL32689807 0.80 ATM (0.32) ATM
SCHEMBL27285075 0.80 ATM (0.32) ATMLGMN
SCHEMBL30819547 0.78 ATM (0.33) ATM
SCHEMBL31716672 0.78 ATM (0.33) ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025226861-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. (US) 2025-10-30 WO disclosed
EP-4605409-A2 CYCLIN INHIBITORS Circle Pharma, Inc. (US) 2025-08-27 EP disclosed
US-20240218021-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-07-04 US disclosed
WO-2024086814-A2 CYCLIN INHIBITORS CIRCLE PHARMA, INC. (US) 2024-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218021-A1 CYCLIN INHIBITORS CCNI, CCNC, CDK2 ATM 563/4885EP300 366/4885LGMN 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.